You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 23, 2024

DATSCAN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Datscan patents expire, and what generic alternatives are available?

Datscan is a drug marketed by Ge Hlthcare Inc and is included in one NDA.

The generic ingredient in DATSCAN is ioflupane i-123. Two suppliers are listed for this compound. Additional details are available on the ioflupane i-123 profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Datscan

A generic version of DATSCAN was approved as ioflupane i-123 by CURIUM on March 30th, 2022.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for DATSCAN?
  • What are the global sales for DATSCAN?
  • What is Average Wholesale Price for DATSCAN?
Summary for DATSCAN
US Patents:0
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 7
Clinical Trials: 17
Patent Applications: 102
What excipients (inactive ingredients) are in DATSCAN?DATSCAN excipients list
DailyMed Link:DATSCAN at DailyMed
Drug patent expirations by year for DATSCAN
Recent Clinical Trials for DATSCAN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
InvicroPhase 1
GE HealthcarePhase 1
PPDPhase 1

See all DATSCAN clinical trials

Pharmacology for DATSCAN

US Patents and Regulatory Information for DATSCAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Hlthcare Inc DATSCAN ioflupane i-123 SOLUTION;INTRAVENOUS 022454-001 Jan 14, 2011 AP RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for DATSCAN

See the table below for patents covering DATSCAN around the world.

Country Patent Number Title Estimated Expiration
Netherlands 300123 ⤷  Sign Up
World Intellectual Property Organization (WIPO) 9639198 ⤷  Sign Up
Germany 69332544 ⤷  Sign Up
European Patent Office 0703791 NEUROSONDE IODEE DESTINEE A LA CARTOGRAPHIE DE SITES DE REABSORPTION DE MONOAMINES (AN IODINATED NEUROPROBE FOR MAPPING MONOAMINE REUPTAKE SITES) ⤷  Sign Up
European Patent Office 0831941 NEUROSONDES IODEES POUR CARTOGRAPHIER LES SITES DE REABSORPTION DE LA MONOAMINE (IODINATED NEUROPROBES FOR MAPPING MONOAMINE REUPTAKE SITES) ⤷  Sign Up
Australia 6159796 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for DATSCAN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0703791 CA 2003 00010 Denmark ⤷  Sign Up
0703791 03C0021 France ⤷  Sign Up PRODUCT NAME: IOFLUPANE (123 I); REGISTRATION NO/DATE: EU/1/00/135/001 20000727
0703791 9/2003 Austria ⤷  Sign Up PRODUCT NAME: IOFLUPANE (123I); REGISTRATION NO/DATE: EU/1/00/135/001 20000727
0703791 SPC/GB03/010 United Kingdom ⤷  Sign Up PRODUCT NAME: IOFLUPANE (123I) OR (123I)-2-BETA-CARBOMETHOXY-3-BETA-(4-IODOPHENYL)-8-(3-FLUOROPROPYL)-NORTROPANE; REGISTERED: UK EU/1/00/135/001 20000802
0703791 C300123 Netherlands ⤷  Sign Up PRODUCT NAME: IOFLUPANE (123I); NAT. REGISTRATION NO/DATE: EU/1/00/135/001 20000727; FIRST REGISTRATION: EU/1/00/135/001 20000727
0703791 300123 Netherlands ⤷  Sign Up
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.